You are here: Industry Insights > J&J

News List

J&J’s Tremfya outperforms Novartis’ Cosentyx in psoriasis pharmaphorum
December 14, 2018
A large head-to-head study has shown Johnson & Johnson’s psoriasis drug Tremfya outperformed Novartis’ rival, Cosentyx, which had previously set standards in moderate to severe disease.
J&J, Merck chip in for $100M U.K. vaccine center fiercepharma
December 11, 2018
To help prepare the post-Brexit U.K.—and potentially the world—for future disease outbreaks, the U.K. government, with help from academic institutions and the pharma industry...
J&J's fast-growing Darzalex lines up for 2nd 1L myeloma nod fiercepharma
December 06, 2018
SAN DIEGO—Johnson & Johnson’s Darzalex made multiple myeloma history this May when it became the first monoclonal antibody to score an FDA approval in newly diagnosed patients. And now, it’s looking to make it a repeat.
J&J makes Xarelto case for clot prevention in cancer fiercepharma
December 06, 2018
SAN DIEGO—Johnson & Johnson's clot-busting Xarelto may not have hit the primary goal in its latest trial...
J&J, Merck chip in for $100M U.K. vaccine center fiercepharma
December 06, 2018
To help prepare the post-Brexit U.K.—and potentially the world—for future disease outbreaks, the U.K. governmen...
J&J touts new immune response data for HIV vaccine fiercepharma
December 04, 2018
Johnson & Johnson has already advanced a “mosaic” HIV vaccine candidate into efficacy testing in five southern African countries...
J&J opens €72M vaccine plant for stepped-up R&D fiercepharma
December 04, 2018
Johnson & Johnson has big ambitions in vaccines, and to get there, its manufacturing has to measure up. The small plant acquired in its Crucell purchase just won't support its advancing pipeline candidates—and certainly not product launches down the road.
J&J shares fall after court refuses to block Zytiga generics pharmaphorum
November 27, 2018
Johnson & Johnson’s share price took a beating this week after the US appeals court declined its bid to stop sales of cheap generic versions of its blockbuster prostate cancer drug Zytiga.
GSK retains leading position on access to medicines list pharmatimes
November 26, 2018
GlaxoSmithKline has retained its top position among a global list of pharmaceutical companies striving to make their medicines, vaccines and diagnostics more accessible for people in low- and middle-income countries.
J&J announce promising Phase 1/2a results for HIV vaccine pharmafile
October 25, 2018
The world may be one step closer to discovering a preventative vaccine for HIV following American multinational Johnson & Johnson's announcement of promising...

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page